Table 3.
Clinical findings in 41 patients with cardiomyopathy evaluated at > 40 years
| Infiltrative cardiomyopathy (n = 11) | HCM (n = 30) | p value | |
|---|---|---|---|
| Age*, years | 68 ± 11 | 62 ± 11 | 0.059 |
| Gender: men, n (%) | 8 (73 %) | 13 (43 %) | 0.095 |
| Hs-cTnT*, ng/ml | 0.083 ± 0.057 | 0.025 ± 0.031 | <0.001 |
| BNP*, pg/ml | 349 ± 301 | 248 ± 203 | 0.332 |
| eGFR, ml/min per 1.73 m2 | 61 ± 17 | 69 ± 19 | 0.220 |
| NYHA functional class, n (%) | 0.124 | ||
| I | 2 (18 %) | 16 (53 %) | |
| II | 8 (73 %) | 13 (43 %) | |
| III | 1 (9 %) | 1 (3 %) | |
| Hx. of heart failure admission, n (%) | 5 (45 %) | 6 (20 %) | 0.111 |
| Maximum LV wall thickness, mm | 17 ± 3 | 20 ± 4 | 0.029 |
| Interventricular wall thickness, mm | 16 ± 3 | 16 ± 4 | 0.562 |
| Posterior wall thickness*, mm | 15 ± 3 | 10 ± 2 | <0.001 |
| LV end-diastolic diameter, mm | 44 ± 5 | 45 ± 6 | 0.877 |
| LV end-systolic diameter*, mm | 32 ± 7 | 28 ± 8 | 0.161 |
| Ejection fraction, % | 54 ± 13 | 61 ± 13 | 0.147 |
| Left atrial diameter, mm | 44 ± 6 | 44 ± 9 | 0.950 |
| E*, cm/s | 89 ± 23 | 69 ± 21 | 0.019 |
| A, cm/s | 67 ± 33 | 67 ± 19 | 0.985 |
| E/A* | 1.7 ± 1.0 | 1.1 ± 0.5 | 0.069 |
| Dct*, msec | 208 ± 81 | 198 ± 70 | 0.825 |
| Ea septal*, cm/s | 3.9 ± 1.1 | 5.0 ± 2.3 | 0.226 |
| Ea lateral*, cm/s | 4.8 ± 1.3 | 7.9 ± 3.3 | <0.001 |
| E/Ea septal | 24 ± 7 | 16 ± 7 | 0.002 |
| E/Ea lateral* | 20 ± 8 | 10 ± 4 | <0.001 |
| Presence of LVOTO, n (%) | 1 (9 %) | 5 (17 %) | 1.000 |
| Presence of RVH, n (%) | 6 (55 %) | 14 (47 %) | 0.655 |
Data are shown as mean ± SD or number (percent)
A mark of * is the results of Wilcoxon rank sum test
HCM Hypertrophic cardiomyopathy, Hs-cTnT High-sensitivity cardiac troponin T, BNP Brain natriuretic peptide, eGFR estimated glomerular filtration rate, NYHA, New York Heart Association functional class, LV Left ventricular, LVOTO Left ventricular outflow tract obstruction, RVH Right ventricular hypertrophy